APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia.
- Author:
Hyery KIM
1
;
Heewon SEO
;
Yoomi PARK
;
Byung Joo MIN
;
Myung Eui SEO
;
Kyung Duk PARK
;
Hee Young SHIN
;
Ju Han KIM
;
Hyoung Jin KANG
Author Information
- Publication Type:Original Article
- Keywords: NUDT15; APEX1; 6-Mercaptopurine; Neutropenia; Acute lymphoblastic leukemia; Pediatrics
- MeSH: 6-Mercaptopurine; Alleles; Computational Biology; Cytochrome P-450 CYP1A1; Cytoprotection; DNA Damage; Genotype; Humans; Incidence; Neutropenia*; Pediatrics; Precursor Cell Lymphoblastic Leukemia-Lymphoma*
- From:Cancer Research and Treatment 2018;50(3):823-834
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Mercaptopurine (MP) is one of the main chemotherapeutics for acute lymphoblastic leukemia (ALL). To improve treatment outcomes, constant MP dose titration is essential to maintain steady drug exposure, while minimizing myelosuppression. We performed two-stage analyses to identify genetic determinants of MP-related neutropenia in Korean pediatric ALL patients. MATERIALS AND METHODS: Targeted sequencing of 40 patients who exhibited definite MP intolerance was conducted using a novel panel of 211 pharmacogenetic-related genes, and subsequent analysis was performed with 185 patients. RESULTS: Using bioinformatics tools and genetic data, four functionally interesting variants were selected (ABCC4, APEX1, CYP1A1, and CYP4F2). Including four variants, 23 variants in 12 genes potentially linked to MP adverse reactions were selected as final candidates for subsequent analysis in 185 patients. Ultimately, a variant allele in APEX1 rs2307486was found to be strongly associated with MP-induced neutropenia that occurred within 28 days of initiating MP (odds ratio, 3.44; p=0.02). Moreover, the cumulative incidence of MP-related neutropenia was significantly higher in patients with APEX1 rs2307486 variants, as GG genotypes were associated with the highest cumulative incidence (p < 0.01). NUDT15 rs116855232 variants were strongly associated with a higher cumulative incidence of neutropenia (p < 0.01), and a lower median dose of tolerated MP throughout maintenance treatment (p < 0.01). CONCLUSION: We have identified that APEX1 rs2307486 variants conferred an increased risk of MP-related early onset neutropenia. APEX1 and NUDT15 both contribute to cell protection from DNA damage or misincorporation, so alleles that impair the function of either gene may affect MP sensitivities, thereby inducing MP-related neutropenia.
